Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value
$24.81+0.34 (+1.39%)
Close on Nov 11, 2026Market cap $807.71MP/E 24.8Yield –
Collegium Pharmaceutical gross margin
Gross margin is gross profit as a percentage of revenue.
Collegium Pharmaceutical's gross margin for the twelve months ending Sep 30, 2026 was 59.0%. For fiscal 2025 it was 59.3%, against 59.8% the year before. The highest annual figure on record is 90.9% in fiscal 2017.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 59.3% | −0.4 |
| FY2024 | Dec 31, 2024 | 59.8% | +2.2 |
| FY2023 | Dec 31, 2023 | 57.5% | +12.4 |
| FY2022 | Dec 31, 2022 | 45.2% | −9.2 |
| FY2021 | Dec 31, 2021 | 54.4% | −3.6 |
| FY2020 | Dec 31, 2020 | 58.0% | +23.3 |
| FY2019 | Dec 31, 2019 | 34.7% | −6.2 |
| FY2018 | Dec 31, 2018 | 40.9% | −50.0 |
| FY2017 | Dec 31, 2017 | 90.9% | +3.3 |
| FY2016 | Dec 31, 2016 | 87.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 58.0% | −3.7 |
| Q2 FY2026 | Jun 30, 2026 | 55.2% | −2.5 |
| Q1 FY2026 | Mar 31, 2026 | 60.6% | +5.8 |
| Q4 FY2025 | Dec 31, 2025 | 62.5% | +8.5 |
| Q3 FY2025 | Sep 30, 2025 | 61.7% | +0.9 |
| Q2 FY2025 | Jun 30, 2025 | 57.7% | −4.9 |
| Q1 FY2025 | Mar 31, 2025 | 54.8% | −8.4 |
| Q4 FY2024 | Dec 31, 2024 | 54.0% | −9.2 |
| Q3 FY2024 | Sep 30, 2024 | 60.8% | +2.0 |
| Q2 FY2024 | Jun 30, 2024 | 62.5% | +8.0 |
| Q1 FY2024 | Mar 31, 2024 | 63.1% | +9.6 |
| Q4 FY2023 | Dec 31, 2023 | 63.2% | +24.8 |
| Q3 FY2023 | Sep 30, 2023 | 58.7% | +12.4 |
| Q2 FY2023 | Jun 30, 2023 | 54.5% | +12.1 |
| Q1 FY2023 | Mar 31, 2023 | 53.5% | −4.4 |
| Q4 FY2022 | Dec 31, 2022 | 38.4% | +43.3 |
| Q3 FY2022 | Sep 30, 2022 | 46.3% | −12.2 |
| Q2 FY2022 | Jun 30, 2022 | 42.4% | −18.2 |
| Q1 FY2022 | Mar 31, 2022 | 57.9% | −5.5 |
| Q4 FY2021 | Dec 31, 2021 | -4.9% | −62.9 |
| Q3 FY2021 | Sep 30, 2021 | 58.5% | −2.4 |
| Q2 FY2021 | Jun 30, 2021 | 60.6% | −1.4 |
| Q1 FY2021 | Mar 31, 2021 | 63.4% | +12.4 |
| Q4 FY2020 | Dec 31, 2020 | 58.1% | +24.2 |
| Q3 FY2020 | Sep 30, 2020 | 60.9% | +25.0 |
| Q2 FY2020 | Jun 30, 2020 | 62.0% | +26.8 |
| Q1 FY2020 | Mar 31, 2020 | 51.0% | +16.9 |
| Q4 FY2019 | Dec 31, 2019 | 33.8% | −25.7 |
| Q3 FY2019 | Sep 30, 2019 | 35.9% | +1.5 |
| Q2 FY2019 | Jun 30, 2019 | 35.2% | −0.7 |
| Q1 FY2019 | Mar 31, 2019 | 34.0% | +1.6 |
| Q4 FY2018 | Dec 31, 2018 | 59.5% | −30.3 |
| Q3 FY2018 | Sep 30, 2018 | 34.4% | −60.9 |
| Q2 FY2018 | Jun 30, 2018 | 35.9% | −47.9 |
| Q1 FY2018 | Mar 31, 2018 | 32.4% | −50.5 |
| Q4 FY2017 | Dec 31, 2017 | 89.9% | +4.0 |
| Q3 FY2017 | Sep 30, 2017 | 95.4% | – |
| Q2 FY2017 | Jun 30, 2017 | 83.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 82.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 85.9% | – |
See a number that looks wrong?